In BRAF mutant melanomas, the combination of targeted and immunotherapy has been tested in preclinical models [7], and clinical trials are currently underway [8, 9], suggesting that a combination of BRAFi, MEK inhibitor, and PD‐1 blockade may be feasible. This evidence concerns the gene MAP2K7 and melanoma.